<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02816931</url>
  </required_header>
  <id_info>
    <org_study_id>540-2013-8797</org_study_id>
    <secondary_id>D0879701</secondary_id>
    <nct_id>NCT02816931</nct_id>
  </id_info>
  <brief_title>Drug Concentrations in the Treatment of MDR-TB Related to Minimum Inhibitory Concentrations</brief_title>
  <acronym>TDM-MDR-TB</acronym>
  <official_title>Plasma Drug Concentrations in the Treatment of Multidrug-resistant Tuberculosis in Relation to Minimum Inhibitory Concentrations - a Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-drug resistant tuberculosis (MDR-TB) is steadily increasing world-wide, urging for the
      need of improved treatment strategies. In order to protect the few available drugs that are
      left, ensuring adequate plasma concentrations of the drugs are important. Individualized
      therapy using plasma drug concentrations and minimal inhibitory concentration (MIC)
      determination may be of importance (1). The plasma drug concentrations and the MICs of the
      second-line drugs will be compared, aiming at increasing the knowledge about
      pharmacokinetic/pharmacodynamic (PK/PD) indices in the treatment of MDR-TB. In the future,
      the aim is an individualised therapy, where sub-therapeutic drug concentrations can be
      adjusted by the use of therapeutic drug monitoring (TDM). TDM in the treatment of MDR-TB may
      improve clinical outcome for the patients, but plasma concentrations must be assessed
      together with clinical and microbiological factors (2).

      In this observational study the hypothesis is that the ratio between drug concentrations and
      MICs of the anti-tuberculous drugs, are correlated to the time to sputum culture conversion,
      the bacterial load measured as time to positive liquid culture (TTP) and clinical outcome.
      Consenting adult patients with pulmonary MDR-TB patients in China will be recruited.
      MIC-determination of Mycobacterium tuberculosis will be performed in BACTEC 960 MGIT and drug
      concentration will be determined at 2, 4 and 8 weeks after treatment initiation using liquid
      chromatography tandem mass spectrometry (LC-MS/MS), simultaneously assessing Dried Blood Spot
      (DBS) as a bio-sampling method. Sputum cultures will be obtained regularly throughout the
      treatment to measure the time to culture positivity (TTP). Clinical follow up according to
      WHO criteria will be performed at the end of treatment completion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consenting adult patients with active pulmonary MDR-TB in the study hospital in China (n=50),
      will be included in the study. Detailed demographic background information as well as
      baseline clinical characteristics will be collected. Sputum samples for culture and Time to
      culture positivity (TTP) will be collected at inclusion and at day 2, 7 and week 2, 4, 8 and
      12 weeks after start of treatment. MIC-determination of Mycobacterium tuberculosis for all
      drugs included in the patient's treatment, will be performed mainly using Sensititre TREK
      kit, complemented with BACTEC 960 MGIT when necessary. After two weeks of TB-treatment,
      plasma drug concentrations of all the drugs used will be collected. Multiple blood samples
      (0, 1, 2, 4, 6, 8 and 10 h after drug intake) will be collected in order to accurately
      calculate the free area under the time-versus concentration curve (fAUC) and maximum
      concentrations (fCmax). The exposure variables are the fAUC and the fCmax and their ratio
      with the MIC for the bacteria of the different drugs. Furthermore, blood sampling to assess
      stability of drug concentrations will be performed at week 8 and week 12 (0, 4 and 6 h
      post-dose). In order to evaluate if low ratios of fAUC/MIC and fCmax/MIC are associated with
      poor clinical outcome, clinical parameters as well as sputum culture conversion, time to
      culture positivity (TTP), inflammatory markers and radiological imaging will be followed up
      during the first three months of treatment. After treatment completion, the WHO criteria for
      defining treatment outcome will be applied.

      Furthermore, a method of simultaneous determination using LC-MS/MS of the second-line drugs
      used, will be developed and compared with the use of Dried Blood Spot assay (DBS). DBS has
      the advantage of enabling drug concentration analysis even in remote areas, since
      transportation of the filter papers is easy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Free area under the curve (fAUC) for second-line TB drugs, separate and in relation to minimum inhibitory concentration (MIC)</measure>
    <time_frame>after 2 weeks of treatment (rich sampling)</time_frame>
    <description>Descriptive data of the distribution of fAUC of MDR-TB patients, with regard to existing recommended levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Free maximal concentration (fCmax) for second-line TB drugs, separate and in relation to minimum inhibitory concentration (MIC)</measure>
    <time_frame>after 2 weeks of treatment (rich sampling)</time_frame>
    <description>Descriptive data of the distribution of fCmax of MDR-TB patients, with regard to existing recommended levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sputum culture conversion</measure>
    <time_frame>3 months of treatment</time_frame>
    <description>The proportion of patient's with sputum culture conversion after 3 months of TB treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum culture conversion</measure>
    <time_frame>2 months of treatment</time_frame>
    <description>The proportion of patient's with sputum culture conversion after 2 months of TB treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to sputum culture positivity (TTP)</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in the TTP during the first 3 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TB score 2 during the first 3 months of treatment</measure>
    <time_frame>3 months</time_frame>
    <description>Decrease or increase of TB score during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in drug resistance - WGS (whole genome sequencing) or MIC</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of patient's with significant changes in the drug resistance, phenotypic (MIC) and genotypic (whole genome sequencing) of the TB drugs used, for patients who are still culture positive after 3 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to sputum culture conversion</measure>
    <time_frame>24 months</time_frame>
    <description>Time (in months) from start of treatment until the first out of two consecutive negative sputum cultures, collected at least 30 days apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment outcome</measure>
    <time_frame>36 months</time_frame>
    <description>Treatment outcome according to the WHO, including relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D Quality of life</measure>
    <time_frame>3months</time_frame>
    <description>Descriptive analysis of EQ-5D during MDR-TB treatment</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Tuberculosis, Multidrug Resistant</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Mycobacterium tuberculosis isolates will be frozen and stored for whole genome sequencing in
      order to compare with clinical and phenotypic characteristics. Blood samples will be frozen
      and stored for drug concentration analysis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients newly diagnosed with pulmonary MDR-TB admitted to the study hospital in
        Xiamen, China is eligible for inclusion. Phenotypic DST results identifying M. tuberculosis
        resistant to rifampicin and isoniazid will be performed. Patient's will be informed and
        asked to participate in the study both orally and in writing.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active pulmonary MDR-TB tuberculosis, consenting adult

        Exclusion Criteria:

          -  HIV, pregnancy, Extensively Drug Resistant TB (XDR-TB), unwilling to participate,
             critically ill such as admitted to the ICU, ongoing treatment with 5 MDR TB drugs or
             more for more than 24 hours.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hu Yi, MD Ass Prof</last_name>
    <role>Study Director</role>
    <affiliation>Fudan University, Shanghai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sven Hoffner, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Biao Xu, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Fudan University, Shanghai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Sch√∂n, MD Ass Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Kalmar County Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rongrong Zheng, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Xiamen CDC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lina Davies Forsman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet, Department of Medicine, Unit of Infectious Diseases, Stockholm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiangyang Yao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Xiamen First Affiliated Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan-Willem Alffenaar, Prof PhamD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center of Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Remco Koster, PhamD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center of Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katarina Niward, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Linkoeping</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Judith Bruchfeld, MD Ass. Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet, Department of Medicine, Unit of Infectious Diseases, Stockholm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jakob Paues, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Linkoeping</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johanna Kuhlin, MD, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lina Davies Forsman, MD</last_name>
    <phone>+46 8 517 70 000</phone>
    <phone_ext>72455</phone_ext>
    <email>lina.davies.forsman@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Judith Bruchfeld, MD Ass prof</last_name>
    <phone>+46 8 517 700 00</phone>
    <email>judith.bruchfeld@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xiamen Designated TB hospital</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rongrong Zheng, MD</last_name>
      <email>rong3018@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014 Jun;74(8):839-54. doi: 10.1007/s40265-014-0222-8. Review. Erratum in: Drugs. 2014 Jun;74(9):2061. Dosage error in article text.</citation>
    <PMID>24846578</PMID>
  </reference>
  <reference>
    <citation>Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, Gumbo T, McIlleron H. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother. 2015 Jan;59(1):38-45. doi: 10.1128/AAC.03931-14. Epub 2014 Oct 13.</citation>
    <PMID>25313213</PMID>
  </reference>
  <reference>
    <citation>Ghimire S, Bolhuis MS, Sturkenboom MG, Akkerman OW, de Lange WC, van der Werf TS, Alffenaar JW. Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics. Eur Respir J. 2016 Jun;47(6):1867-9. doi: 10.1183/13993003.00040-2016. Epub 2016 Mar 17.</citation>
    <PMID>26989104</PMID>
  </reference>
  <reference>
    <citation>van der Burgt EP, Sturkenboom MG, Bolhuis MS, Akkerman OW, Kosterink JG, de Lange WC, Cobelens FG, van der Werf TS, Alffenaar JW. End TB with precision treatment! Eur Respir J. 2016 Feb;47(2):680-2. doi: 10.1183/13993003.01285-2015.</citation>
    <PMID>26828056</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Judith Bruchfeld</investigator_full_name>
    <investigator_title>Senior Consultant, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Treatment</keyword>
  <keyword>Drug Monitoring</keyword>
  <keyword>Minimum Inhibitory Concentration</keyword>
  <keyword>Dried Blood Spot Method</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

